科技广药丨白云山光华制药自主研发的儿童小柴胡颗粒研究启动II期临床试验

广药白云山
Oct 15, 2025

近日,广药集团旗下上市公司白云山(SH600332/HK0874)发布公告,子公司白云山光华制药自主研发的儿童小柴胡颗粒于近日在国家药品监督管理局药品审评中心(CDE)药物临床试验登记与信息公示平台公示了II期临床试验登记信息(登记号:CTR20253842)。这标志着我国针对小儿胃肠型感冒适应症的首个中药新药研究实现关键突破,并正式启动临床试验。守正创新:破解儿童用药难题小儿胃肠型感冒作为儿科...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10